Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

OBJECTIVES: To compare efficacy and safety of various doses of tofacitinib, an oral Janus kinase inhibitor, with placebo in patients with active ankylosing spondylitis (AS, radiographic axial spondyloarthritis). METHODS: In this 16-week (12-week treatment, 4-week washout), phase II, multicentre, dos...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, Désirée, Deodhar, Atul, Wei, James C, Drescher, Edit, Fleishaker, Dona, Hendrikx, Thijs, Li, David, Menon, Sujatha, Kanik, Keith S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738601/
https://www.ncbi.nlm.nih.gov/pubmed/28130206
http://dx.doi.org/10.1136/annrheumdis-2016-210322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738601/
https://www.ncbi.nlm.nih.gov/pubmed/28130206
http://dx.doi.org/10.1136/annrheumdis-2016-210322

Ejemplares similares